You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy
SBC: Enzyme by Design Inc. Topic: 102PROJECT SUMMARY Enzyme by DesignIncEbDis developing a safer version of L asparaginase that can be used routinely in the treatment of adult ALL patients whose hypersensitivity to todayandapos s bacterial L asparaginases deprives them from this efficacious therapyEbDandapos s L asparaginase is novel due to its mammalianguinea pigorigin and its lack of L glutaminase co activityThe need for better the ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimization of Novel Ryanodine Receptor Modulatory Compounds for Alzheimer's Disease
SBC: NeuroLucent Topic: NIAAbstract Summary Currentlythere are no effective treatments to preserve cognitive function in AD patients and the recent series of disappointing clinical trials highlight the need to explore alternative pathwaysTo this endNeuroLucent Incand its academic partnerRFUMSare developing small molecule compounds designed as allosteric modulators of the ryanodine receptorRyRa high conductance calcium chann ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Wireless Implantable Neural Recording Device
SBC: Neurolux, Inc. Topic: 105Project Summary NeuroLux Increcently developed and commercialized a fully implantablewireless optogeneticLED stimulator that istimes smaller by volume andtimes lighter in weight than current state of the art methodologywww neurolux org productsWith this technologythe neural circuitry of an unrestrictedfreely moving animal can be manipulated on demandallowing us to study the dynamic effects of neur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure
SBC: ToleRaM NanoTech LLC Topic: NIBIBABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil
SBC: AcePre, LLC Topic: NCCIHPROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Robust Predictor of Colon Cancer Risk
SBC: Morgan and Mendel Genomics, Inc. Topic: 102Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel safe and efficacious biologic drug for the treatment of AML
SBC: Enzyme by Design Inc. Topic: OPROJECT SUMMARY There is a clear unmet need for effective treatments for acute myeloid leukemiaAMLAn exciting new mechanism for targeting cancer cells involves the activation of the extrinsic apoptotic pathway by administering the soluble domain of TNF related apoptosis inducing ligandTRAILcalled dulanerminMuch hope has been placed on this drug since TRAIL has been shown to bind to death receptors ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health